MEDP · XBRL financial data

Medpace Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MEDP's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	926	1,142	1,460	1,886	2,109	2,530
Selling, general and administrative	92	108	131	161	180	198
Operating income (loss)	167	199	279	337	447	535
Other income (expense)	1	3	7	(1)	4	(5)
Income tax expense (benefit)	23	20	37	53	72	91
Net income (loss)	145	182	245	283	404	451
Earnings per share, basic USD per share	4.07	5.06	7.57	9.20	13.06	15.64
Earnings per share, diluted USD per share	3.84	4.81	7.28	8.88	12.63	15.28
Weighted average shares, basic millions of shares	36	36	32	31	31	29
Weighted average shares, diluted millions of shares	38	38	34	32	32	30

Fiscal years (MEDP's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	278	461	28	245	669	497
Prepaid and other current assets	35	43	52	50	63	90
Total current assets	474	691	334	594	1,029	990
Property and equipment, net	85	93	110	121	124	131
Right-of-use asset	114	130	139	145	129	118
Goodwill	662	662	662	662	662	662
Total assets	1,391	1,660	1,352	1,657	2,101	1,975
Accounts payable	27	26	33	32	33	28
Accrued liabilities	134	159	210	293	308	408
Total current liabilities	440	557	803	925	1,105	1,344
Lease liability, non-current	115	131	139	142	126	114
Total liabilities	585	707	966	1,098	1,275	1,516
Retained earnings (accumulated deficit)	115	235	(360)	(222)	8	(460)
Total stockholders' equity	806	953	386	559	826	459
Total liabilities and equity	1,391	1,660	1,352	1,657	2,101	1,975
Common shares outstanding (cover page) millions of shares	36	35	31	31	30	28

Fiscal years (MEDP's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	145	182	245	283	404	451
Stock-based compensation	14	14	21	21	26	35
Net cash from operating activities	259	263	388	433	609	713
Purchases of property and equipment	31	28	37	37	37	31
Net cash from investing activities	(31)	(31)	(39)	(35)	(28)	(31)
Share repurchases	98	62	848	144	170	917
Net cash from financing activities	(82)	(44)	(776)	(183)	(154)	(860)
Net change in cash	146	184	(433)	217	424	(172)

SIC 8731 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8731 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Medpace Holdings	705	716	217*	28.0M	Q3 FY26 10-QSep 30, 2026
Charles River Laboratories International	200	983	254*	47.9M	Q3 FY26 10-QSep 26, 2026
UL Solutions	1,016	823	215*	not reported	Q3 FY26 10-QSep 30, 2026
Incyte	3,276	1,557	(675)*	203.8M	Q3 FY26 10-QSep 30, 2026
Iqvia Holdings	2,249	4,428	825*	164.8M	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 8, 2026, 6:22 AM ET. The filing on SEC.gov is the record.